Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Telix Pharmaceuticals (TLX) Current Assets (2023 - 2025)

Telix Pharmaceuticals has reported Current Assets over the past 3 years, most recently at $330.3 million for Q4 2025.

  • Quarterly Current Assets fell 45.02% to $330.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $330.3 million through Dec 2025, down 45.02% year-over-year, with the annual reading at $330.3 million for FY2025, 42.07% down from the prior year.
  • Current Assets was $330.3 million for Q4 2025 at Telix Pharmaceuticals, down from $600.7 million in the prior quarter.
  • Over five years, Current Assets peaked at $600.7 million in Q4 2024 and troughed at $151.4 million in Q4 2023.
  • The 3-year median for Current Assets is $330.3 million (2025), against an average of $360.8 million.
  • Year-over-year, Current Assets soared 296.87% in 2024 and then tumbled 45.02% in 2025.
  • A 3-year view of Current Assets shows it stood at $151.4 million in 2023, then soared by 296.87% to $600.7 million in 2024, then plummeted by 45.02% to $330.3 million in 2025.
  • Per Business Quant, the three most recent readings for TLX's Current Assets are $330.3 million (Q4 2025), $600.7 million (Q4 2024), and $151.4 million (Q4 2023).